Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Hellmann

Showing results (111-120 of 172) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Treatment Outcomes of Immune-Related Cutaneous Adverse EventsGregory S Phillips, Jennifer Wu, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell AnalysisIla Datar, Miguel F Sanmamed, Jun Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsKyung Hae Jung, Patricia LoRusso, Howard Burris, et al.
Nature Medicine|July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.
Nature|June 18, 2019
TOX is a critical regulator of tumour-specific T cell differentiationAndrew C Scott, Friederike Dündar, Paul Zumbo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.
The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancerEdward B Garon, Naiyer A Rizvi, Rina Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.
Pageof 18

Showing results (111-120 of 172) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Treatment Outcomes of Immune-Related Cutaneous Adverse EventsGregory S Phillips, Jennifer Wu, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell AnalysisIla Datar, Miguel F Sanmamed, Jun Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsKyung Hae Jung, Patricia LoRusso, Howard Burris, et al.
Nature Medicine|July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.
Nature|June 18, 2019
TOX is a critical regulator of tumour-specific T cell differentiationAndrew C Scott, Friederike Dündar, Paul Zumbo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.
The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancerEdward B Garon, Naiyer A Rizvi, Rina Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.
Pageof 18